SecBot SecBot
144 ·Filed Jun 4, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001959173-26-004324
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Form 144 signals intent to sell, not a completed transaction. The small dollar amount relative to market cap and routine nature (post-RSU vesting) make this a neutral event. No immediate trading signal; monitor for any follow-on Form 4 filings to confirm execution.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.67
T+0 close · Jun 4, 2026 · via day close
Latest settled
+13.63%
T+60 · $25.76
Vs SPY
+11.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $22.67entry
  2. T+1 · 6mo ago +0.35%α +2.95% · $22.75
  3. T+5 · 5mo ago +3.04%α +5.60% · $23.36
  4. T+20 · 4mo ago +12.00%α +13.37% · $25.39
  5. T+60 · 3mo ago +13.63%α +11.75% · $25.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, valued at approximately $228,468 based on a June 4, 2026 market price of $22.28. The shares were acquired through restricted stock vesting on June 3, 2026, as compensation. The sale is a routine post-vesting monetization by an officer, representing a small fraction of the company's $878M market cap, and does not signal material insider concern.

Key Facts

  • Officer Kristen Williams filed Form 144 to sell 10,259 shares of PCRX common stock
  • Proceeds estimated at ~$228,468 based on filing date price (~$22.28/share)
  • Shares acquired via restricted stock vesting on June 3, 2026 (compensation)
  • Sale executed through Fidelity Brokerage Services LLC
  • Company market cap ~$878M; proposed sale ~0.026% of outstanding shares
  • Reporting owner is an officer of Pacira BioSciences

Financial Impact

Proposed sale of ~$228K in shares, ~0.026% of market cap, immaterial

dilution

Risk Factors

  • Insider could still execute the sale, but magnitude is too small to affect stock
  • No material negative signal from an officer selling RSU shares for cash

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004324
Document: 0001959173-26-004324-index.html0001959173-26-004324
Document: 0001959173-26-004324.txt0001959173-26-004324

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026